Aurobindo Pharma: Vaccine and API plans inject add-on growth levers

Trading Calls - Equity F&O

In the injectables space, Aurobindo Pharma remains constructive and targets to almost double from current annual sales base of $ 380 million to $ 650-700 million in three years backed by new plants in the US and Vizag

Anubhav Sahu